Lung Cancer Clinical Trial
— PROLUCAOfficial title:
Perioperative Rehabilitation in Operation for Lung Cancer
Background: Improved surgical techniques combined with effective adjuvant chemotherapy, has
led to a better survival in individuals with NSCLC. The treatment of NSCLC and other cancer
diseases are after all still complex and potentially lethal.
Study aim: The rationale for the study PROLUCA is to identify the optimal timing of exercise
to improve recovery after surgery in patients operated for lunge cancer with focus on
physical capacity and quality of life.
Who can participate? Patients above 18 years and diagnosed with lung cancer and referred for
operation. Participation in this study is not possible if the participants by a doctor are
advised not to do strenuous exercise.
What does the study involve? The intervention consists of a combination of (1) exercise
before surgery and (2) exercise after surgery for lung cancer.
1. Exercise before surgery is a home-based exercise program is individually designed and
must be performed for at least 30 minutes every day until surgery. The home-based
exercise program varies in length due to number of days until surgery, and the
intention is not exceed 14 days.
2. The exercise initiated two weeks and 6 weeks after surgery consists of a 12 weeks
rehabilitation program and three individual counseling sessions. Special needs in terms
of smoking cessation, nutritional counseling or patient education, this is also
offered. The exercise consists of individually prepared supervised strength - and
fitness exercise in a team, two sessions of 60 minutes/week.
What interventions will be compared? A home-based post-operative exercise program, combined
with exercise initiated two weeks after surgery, will be compared with usual care (exercise
initiated six weeks after surgery).
Will all participants receive the same treatment?
By draw it is decided which of the 4 groups the participants will attend to in the study:
- Group 1: Home-based exercise before surgery and rehabilitation initiated as early as
two weeks after surgery
- Group 2: Home-based exercise before surgery and rehabilitation initiated six weeks
after surgery
- Group 3: Rehabilitation initiated as early as two weeks after surgery
- Group 4: Rehabilitation initiated six weeks after surgery (Usual practice as control
group) What are the possible benefits and risks of participating? There are no risks or
side- effects of participating other than muscle soreness and exercise is beneficial
when it comes to recover from an operation from lung cancer.
Status | Terminated |
Enrollment | 40 |
Est. completion date | January 2015 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Performance status 0-2 (WHO) - Living in the City of Copenhagen or surrounding Municipalities - Ability to read and understand Danish - Approval by primary surgeon Exclusion Criteria: - Presence of metastatic disease or surgical inoperability - Diagnosis of Lung Cancer not verified by histological diagnosis - Cardiac disease |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Denmark | Copenhagen Centre for Cancer and Health | Copenhagen | Nørrebro |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark | Centre for Integrated Rehabilitation of Cancer patients, CIRE, Denmark, Copenhagen Centre for Cancer and Health, Denmark., Danish Cancer Society, Novo Nordisk A/S, University of Copenhagen |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum oxygen uptake (VO2peak) | VO2peak is evaluated by an incremental test using an electromagnetically braked cycle ergometer (Lode Corival Ergometer©). Inspired and expired gases are analyzed breath-by-breath by a metabolic cart (JAEGER MasterScreen CPX©). Subjects begin pedaling at seven watts and resistance increases after a predefined 10 watts ramp protocol until exhaustion or a symptom-limited VO2peak is achieved (pain, dizziness, anxiety etc.). | VO2peak is assessed at baseline, the day before surgery, post-intervention (14/18 weeks after surgery), six months after surgery, and one year after surgery. | No |
Secondary | Six minute walk distance (6MWD) | baseline, the day before surgery, pre-intervention (2/6 weeks after surgery), post-intervention (14/18 weeks after surgery), six months after surgery, and one year after surgery. | No | |
Secondary | Patient reported outcomes (PROs) | PROs will include health related quality of life, symptoms and side-effects, anxiety and depression, well-being, distress, lifestyle, sickness absence, work status, and social support. | Baseline, the day before surgery, pre-intervention (2/6 weeks after surgery), post-intervention (14/18 weeks after surgery), six months after surgery, and one year after surgery. | No |
Secondary | Pulmonary function | forced expiratory volume at one second | Baseline, the day before surgery, post-intervention (14/18 weeks after surgery), six months after surgery, and one year after surgery. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|